ClinicalTrials.gg
Active, not recruitingNCT06578247QuANTUM-WILDUpdated Jul 2, 2026

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

A Phase 3 interventional study of Quizartinib and Placebo in Leukemia, sponsored by Daiichi Sankyo. Active, not recruiting at 284 sites in 28 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Planned enrollment
2nd of 28
700 · median 69
Started
2024
with 2 others
Phase 3
5 of 28
1 open now
Registered
26th of 28
by date
Lead sponsor
10 of 28
Daiichi Sankyo

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2024, is one of 5 in phase 3, and was the 26th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).

Read the detailed description

This is a clinical trial to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as maintenance therapy for up to 36 cycles) on the primary endpoint of overall survival (OS) in adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML). Participants will be tested for FLT3-ITD mutation status in a central laboratory using a validated assay.

03

Conditions studied

  • Leukemia

Browse trials for

Keywords

  • acute myeloid leukemia
  • quizartinib
  • FLT3
  • FLT3-ITD
  • Chemotherapy
  • FLT3-WT
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 700 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)- or Institutional Review Board (IRB)-approved ICF before performance of any trial-specific procedures or tests.
  2. ≥18 years or the minimum legal adult age (whichever is greater) and ≤70 years (at Screening).
  3. Newly diagnosed, morphologically documented primary AML based on the World Health Organization (WHO) 2016 classification (at Screening)
  4. (ECOG) performance status (at the time the participant signs their ICF) of 0-2.
  5. Participant is a candidate for standard "7+3" induction chemotherapy regimen as specified in the protocol per investigator assessment

Key Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
  2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy.
  3. Diagnosis of AML with known antecedent myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and others.
  4. Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD [+]) present at ≥5% VAF (or ≥0.05 SR) based on a validated FLT3 mutation assay.
  5. Prior treatment for AML, except for the following allowances prior to Day 1 of chemotherapy:

    1. Leukapheresis;
    2. Treatment for hyperleukocytosis with hydroxyurea;
    3. Cranial radiotherapy for central nervous system (CNS) leukostasis;
    4. Prophylactic intrathecal chemotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Arm A: Quizartinib + Chemotherapy

    Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive quizartinib at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)

    Drug: Quizartinib · Drug: Chemotherapy

  • Placebo comparator
    Arm B: Placebo + Chemotherapy

    Participants will receive placebo at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)

    Drug: Placebo · Drug: Chemotherapy

  • Experimental
    Arm C: Quizartinib + Chemotherapy then Placebo Maintenance

    Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)

    Drug: Quizartinib · Drug: Placebo · Drug: Chemotherapy

Interventions

  • Participants will receive quizartinib at 60 mg/day orally once daily

    Also known as: Test Product

  • DrugPlacebo

    Participants will receive placebo at 60 mg/day orally once daily

    Also known as: Placebo Control

  • DrugChemotherapy

    Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).

    Also known as: Cytarabine, Daunorubicin or Idarubicin, Standard Chemotherapy

07

What researchers measure

Primary outcomes

  1. Overall Survival (Arm A vs Arm B)

    Overall survival (OS) is defined as the time from randomization until death from any cause.

    Time frame: Date of first patient randomized to the target number of deaths reached, up to approximately 42 months

Secondary outcomes

  1. Event-free survival (Arm A vs. Arm B)

    Event-free survival (EFS) is defined as time from randomization to date of failure to achieve CR at end of induction, relapse after CR, or death due to any cause, whichever occurs first

    Time frame: Date of randomization up to approximately 42 months

  2. Duration of complete response (Arm A vs. Arm B)

    Duration of complete response (DoCR) is defined as time from the first documented CR until documented relapse or death due to any cause, whichever comes first. As assessed by Independent Review Committee.

    Time frame: Date of randomization up to approximately 42 months

  3. Relapse-free survival (Arm A vs. Arm B)

    Relapse-free survival (RFS) is defined as time from randomization, for participants who achieve CR in the Induction Phase, until relapse or death due to any cause, whichever comes first. As assessed by Independent Review Committee .

    Time frame: Date of randomization up to approximately 42 months

  4. Complete remission rate (Arm A vs. Arm B)

    Complete remission rate (CR) is defined as proportion of of participants who achieved a CR. As assessed by Independent Review Committee.

    Time frame: At end of Induction Phase, up to approximately 120 days

  5. Complete remission rate with minimal or measurable residual disease (Arm A vs. Arm B)

    Proportion of participants achieving CR with minimal or measurable residual disease (MRD) negativity. As assessed by Independent Review Committee.

    Time frame: At end of Induction Phase (Cycle 2 or Cycles 1 and 2), up to approximately 120 days

  6. Number of Participants With Treatment-emergent Adverse Events (Arm A vs. Arm B)

    Treatment-emergent adverse events (TEAE) are defined as those AEs with start or worsening date during the on-treatment period (from the first dose date of quizartinib/placebo to 30 days after the last dose date of quizartinib/placebo).

    Time frame: Date of first dose up to 30 days after last dose, up to approximately 42 months

08

Study locations

284 sites

Showing the first 100 of 284 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Recher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul 11:1-12. doi: 10.1080/14796694.2026.2689464. Online ahead of print. PubMed 42434847 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2030, 67 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 67 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 29, 2024
StartActual
Nov 19, 2024
Primary completionEst.
Jun 26, 2030
CompletionEst.
Jun 26, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06578247
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Nov 19, 2024
Primary completion
Jun 26, 2030 (estimated)
Completion
Jun 26, 2030 (estimated)
Last update
Jul 2, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion